APRE
Aprea Therapeutics Inc

8,343
Loading...
Loading...
News
all
press releases
Wedbush Initiates a Buy Rating on Aprea Therapeutics (APRE)
In a report released today, Robert Driscoll from Wedbush initiated coverage with a Buy rating on Aprea Therapeutics (APRE Research Report) and a...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Analysts Are Bullish on These Healthcare Stocks: Aprea Therapeutics (APRE), TScan Therapeutics (TCRX)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aprea Therapeutics (APRE Research Report) and TScan Therapeutics...
TipRanks Financial Blog·1y ago
News Placeholder
Alltrna Announces Updates to Its Board of Directors
Alltrna Announces Updates to Its Board of Directors Alltrna Announces Updates to Its Board of Directors PR Newswire CAMBRIDGE, Mass., July 17, 2024 Chris Schade appointed as Board ChairpersonLynne...
PR Newswire·1y ago
News Placeholder
Aprea Therapeutics files to sell 4.39M shares of common stock for holders
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Wedbush Boosts Aprea Therapeutics (NASDAQ:APRE) Price Target to $11.00
Aprea Therapeutics (NASDAQ:APRE - Free Report) had its target price lifted by Wedbush from $9.00 to $11.00 in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has...
Zolmax·1y ago
News Placeholder
Brokers Set Expectations for Aprea Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:APRE)
Aprea Therapeutics, Inc. (NASDAQ:APRE Free Report) Equities researchers at Wedbush reduced their Q1 2024 EPS estimates for shares of Aprea Therapeutics in a research report issued on...
Ticker Report·1y ago
News Placeholder
Buy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024
Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE Research Report), with a price target of $20.00...
TipRanks Financial Blog·1y ago
News Placeholder
Aprea Therapeutics: Q4 Earnings Insights
read more...
Benzinga·1y ago
News Placeholder
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly...
Globe Newswire·1y ago
News Placeholder
Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Bernd R. Seizinger Purchases 6,860 Shares
Aprea Therapeutics, Inc. (NASDAQ:APRE Get Free Report) Director Bernd R. Seizinger acquired 6,860 shares of the firms stock in a transaction on Wednesday, March 13th. The stock was...
Ticker Report·1y ago

Latest APRE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.